EGFR- and HER3-targeted bispecific antibody‑drug conjugate demonstrates antitumor activity in metastatic castration‑resistant prostate cancer
A bispecific antibody‑drug conjugate that targets both EGFR and HER3 shows antitumor activity in metastatic castration‑resistant prostate cancer
Bizonyítékszint: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Kapcsolódó jelek
- Apalutamide Treatment and Metastasis‑free Survival in Prostate Cancer
- The prostate cancer conundrum revisited: Treatment changes and prostate cancer mortality declines
- The contemporary management of prostate cancer
- Extracellular TROP2 Fragment Identified as a Potential Biomarker and Metastasis Driver
- Overall survival of prostate cancer patients treated with Lu‑177 PSMA 617 (Pluvicto®) in a multidisciplinary setting— a single center experience